{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:34:47Z","timestamp":1788471287389,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["106680\/Z\/14\/Z"],"award-info":[{"award-number":["106680\/Z\/14\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021734","name":"Leprosy Research Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017714","name":"Turing Foundation","doi-asserted-by":"publisher","award":["FP20.4\/708.20.04"],"award-info":[{"award-number":["FP20.4\/708.20.04"]}],"id":[{"id":"10.13039\/100017714","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Southeast Asia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.lansea.2025.100555","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T06:03:51Z","timestamp":1740549831000},"page":"100555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Challenges associated with dapsone for leprosy treatment in Indonesia - urgent need for access to alternative antimicrobial drugs"],"prefix":"10.1016","volume":"34","author":[{"given":"Hana","family":"Krismawati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Harianja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonius","family":"Oktavian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0927-1520","authenticated-orcid":false,"given":"Claus","family":"B\u00f8gh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Messe R.","family":"Ataupah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth D.","family":"Laiskodat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arry","family":"Pongtiku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Geluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Kevin","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5007-7896","authenticated-orcid":false,"given":"Raph L.","family":"Hamers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardyanto","family":"Soebono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7335-7313","authenticated-orcid":false,"given":"Marlous L.","family":"Grijsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lansea.2025.100555_bib1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41572-024-00575-1","article-title":"Leprosy","volume":"10","author":"Grijsen","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.lansea.2025.100555_bib2","series-title":"Guidelines for the Diagnosis, Treatment and Prevention of Leprosy","year":"2017"},{"issue":"2","key":"10.1016\/j.lansea.2025.100555_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2024.103745","article-title":"Late relapses in leprosy patients in Brazil: 10-year post-trial of uniform multidrug therapy (U-MDT\/CT-BR)","volume":"28","author":"Penna","year":"2024","journal-title":"Braz J Infect Dis"},{"issue":"4","key":"10.1016\/j.lansea.2025.100555_bib4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.47276\/lr.90.4.388","article-title":"Levels of disability and relapse in Bangladeshi MB leprosy cases, 10 years after treatment with 6m MB-MDT","volume":"90","author":"Butlin","year":"2019","journal-title":"Lepr Rev"},{"key":"10.1016\/j.lansea.2025.100555_bib5","series-title":"Global Leprosy (Hansen's Disease) Strategy 2021\u20132030","year":"2021"},{"issue":"2","key":"10.1016\/j.lansea.2025.100555_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00403-013-1409-7","article-title":"Dapsone in dermatology and beyond","volume":"306","author":"Wozel","year":"2014","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"10.1016\/j.lansea.2025.100555_bib7","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40257-024-00879-8","article-title":"Dapsone use in dermatology","volume":"25","author":"Lovell","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.lansea.2025.100555_bib8","doi-asserted-by":"crossref","first-page":"96","DOI":"10.47276\/lr.93.2.96","article-title":"Safer and newer antimicrobial drugs for leprosy \u2013 time to test monthly ROM in an adequately powered randomised trial?","volume":"93","author":"Lockwood","year":"2022","journal-title":"Lepr Rev"},{"issue":"2","key":"10.1016\/j.lansea.2025.100555_bib9","first-page":"197","article-title":"Adverse Drug Reactions (ADR) necessitating modification of multi-drug therapy (MDT) in Hansen's disease: a retrospective study from Kerala, India","volume":"88","author":"Ambooken","year":"2017","journal-title":"Lepr Rev"},{"key":"10.1016\/j.lansea.2025.100555_bib10","first-page":"73","article-title":"Adverse reactions in leprosy patients who underwent dapsone multidrug therapy: a retrospective study","volume":"9","author":"Guragain","year":"2017","journal-title":"Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.lansea.2025.100555_bib11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.47276\/lr.83.3.305","article-title":"Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy","volume":"83","author":"Deps","year":"2012","journal-title":"Lepr Rev"},{"issue":"4","key":"10.1016\/j.lansea.2025.100555_bib12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/jamadermatol.2017.6484","article-title":"Association between HLA-B\u22171301 and dapsone-induced cutaneous adverse drug reactions: a systematic review and meta-analysis","volume":"154","author":"Tangamornsuksan","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.lansea.2025.100555_bib13","doi-asserted-by":"crossref","first-page":"232","DOI":"10.47276\/lr.91.3.232","article-title":"The adverse drug effects of dapsone therapy in leprosy: a systematic review","volume":"91","author":"Hilder","year":"2020","journal-title":"Lepr Rev"},{"issue":"37","key":"10.1016\/j.lansea.2025.100555_bib14","first-page":"501","article-title":"Global leprosy (Hansen disease) update, 2023: elimination of leprosy disease is possible \u2013 time to act!","volume":"99","year":"2024","journal-title":"Wkly Epidemiol Rec"},{"issue":"3","key":"10.1016\/j.lansea.2025.100555_bib15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1258\/004947507781524700","article-title":"Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal","volume":"37","author":"Pandey","year":"2007","journal-title":"Trop Doct"},{"issue":"2","key":"10.1016\/j.lansea.2025.100555_bib16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2340\/00015555-1268","article-title":"Hypersensitivity reactions to dapsone: a systematic review","volume":"92","author":"Lorenz","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"17","key":"10.1016\/j.lansea.2025.100555_bib17","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B\u221713:01 and the dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.lansea.2025.100555_bib18","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1080\/14740338.2020.1796965","article-title":"The HLA-B\u221713:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses","volume":"19","author":"Park","year":"2020","journal-title":"Expet Opin Drug Saf"},{"issue":"10","key":"10.1016\/j.lansea.2025.100555_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008746","article-title":"Validation study of HLA-B\u221713:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia","volume":"14","author":"Krismawati","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"10.1016\/j.lansea.2025.100555_bib20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.47276\/lr.90.4.371","article-title":"Case-control study measuring the association between HLA-B\u221713:01 and dapsone hypersensitivity syndrome in Indian patients","volume":"90","author":"Chiramel","year":"2019","journal-title":"Lepr Rev"},{"issue":"12","key":"10.1016\/j.lansea.2025.100555_bib21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/FPC.0000000000000306","article-title":"Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with\u00a0HLA-B\u221713: 01 allele in the Thai population","volume":"27","author":"Tempark","year":"2017","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"10.1016\/j.lansea.2025.100555_bib22","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamadermatol.2018.5360","article-title":"Evaluation of prospective HLA-B\u221713:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy","volume":"155","author":"Liu","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.lansea.2025.100555_bib23","series-title":"Papua Province Annual Report of Leprosy","year":"2020"},{"key":"10.1016\/j.lansea.2025.100555_bib24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.12688\/wellcomeopenres.19455.1","article-title":"Metformin as adjunctive therapy in combination with multidrug treatment for multibacillary leprosy: a protocol for a randomized double-blind, controlled phase 2 trial in Indonesia (MetLep Trial)","volume":"8","author":"Krismawati","year":"2023","journal-title":"Wellcome Open Res"},{"issue":"5","key":"10.1016\/j.lansea.2025.100555_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057173","article-title":"Implementation of genetic screening test to reduce the incidence of dapsone hypersensitivity syndrome among patients with leprosy in Papua, Indonesia: a study protocol","volume":"12","author":"Krismawati","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.lansea.2025.100555_bib26","first-page":"1","article-title":"Chemotherapy of leprosy. Report of a WHO study group","volume":"847","year":"1994","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"9606","key":"10.1016\/j.lansea.2025.100555_bib27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(08)60073-2","article-title":"Glucose-6-phosphate dehydrogenase deficiency","volume":"371","author":"Cappellini","year":"2008","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.lansea.2025.100555_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001339","article-title":"G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map","volume":"9","author":"Howes","year":"2012","journal-title":"PLoS Med"},{"key":"10.1016\/j.lansea.2025.100555_bib29","article-title":"Leprosy identified in Sumba Island, eastern Indonesia: elimination targets under threat","volume":"26","author":"Siregar","year":"2024","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"2","key":"10.1016\/j.lansea.2025.100555_bib30","doi-asserted-by":"crossref","first-page":"760","DOI":"10.4269\/ajtmh.19-0780","article-title":"Prevalence of glucose 6-phosphate dehydrogenase variants in malaria-endemic areas of South central timor, eastern Indonesia","volume":"103","author":"Sulistyaningrum","year":"2020","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"10.1016\/j.lansea.2025.100555_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003602","article-title":"G6PD deficiency at Sumba in Eastern Indonesia is prevalent, diverse and severe: implications for primaquine therapy against relapsing Vivax malaria","volume":"9","author":"Satyagraha","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"10.1016\/j.lansea.2025.100555_bib32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.47276\/lr.78.3.216","article-title":"Adverse effects from multi-drug therapy in leprosy: a Brazilian study","volume":"78","author":"Deps","year":"2007","journal-title":"Lepr Rev"},{"issue":"3","key":"10.1016\/j.lansea.2025.100555_bib33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1590\/abd1806-4841.20186709","article-title":"Clinical trial for uniform\u00a0multidrug therapy for leprosy patients in Brazil (U-MDT\/CT-BR): adverse effects approach","volume":"93","author":"Cruz","year":"2018","journal-title":"An Bras Dermatol"},{"issue":"12","key":"10.1016\/j.lansea.2025.100555_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012699","article-title":"A\u00a0retrospective cohort study of monthly rifampicin, ofloxacin and minocycline in the management of leprosy at the Hospital for Tropical Diseases, London, United Kingdom","volume":"18","author":"Sivakumaran","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.lansea.2025.100555_bib35","article-title":"Novel approaches in the treatment of Hansen's disease (Leprosy): a case series of multidrug therapy of monthly rifampin, moxifloxacin, and minocycline (RMM) in the United States","volume":"9","author":"Franco-Paredes","year":"2022","journal-title":"Ther Adv Infect Dis"},{"issue":"1","key":"10.1016\/j.lansea.2025.100555_bib36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.47878\/hi.2007.v32.35194","article-title":"A\u00a0therapeutic study comparing the association of rifampin, ofloxacin and minocycline with the association of rifampin, clofazimine and dapsone in multibacillary leprosy","volume":"32","author":"Ura","year":"2007","journal-title":"Hansen Int"},{"issue":"12","key":"10.1016\/j.lansea.2025.100555_bib37","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.cmi.2018.02.022","article-title":"Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15","volume":"24","author":"Cambau","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.lansea.2025.100555_bib38","doi-asserted-by":"crossref","first-page":"425","DOI":"10.47276\/lr.79.4.425","article-title":"A\u00a0retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone","volume":"79","author":"Sapkota","year":"2008","journal-title":"Lepr Rev"},{"issue":"1","key":"10.1016\/j.lansea.2025.100555_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011901","article-title":"Development of a multivariate predictive model for dapsone adverse drug events in people with leprosy under standard WHO multidrug therapy","volume":"18","author":"de Araujo","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.lansea.2025.100555_bib40","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/cpt.1944","article-title":"Global frequencies of clinically important HLA alleles and their implications for the cost-effectiveness of preemptive pharmacogenetic testing","volume":"109","author":"Zhou","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.lansea.2025.100555_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011379","article-title":"Minimal effective dose of bedaquiline administered orally and activity of a long acting formulation of bedaquiline in the murine model of leprosy","volume":"17","author":"Chauffour","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"10.1016\/j.lansea.2025.100555_bib42","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/ijd.17485","article-title":"Exploring the therapeutic and prophylactic potential of bedaquiline in leprosy","volume":"64","author":"Khera","year":"2025","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.lansea.2025.100555_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01436-21","article-title":"Safety, tolerability, and pharmacokinetics of telacebec (Q203), a new antituberculosis agent, in healthy subjects","volume":"66","author":"Kim","year":"2022","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The Lancet Regional Health - Southeast Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772368225000265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772368225000265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T12:26:25Z","timestamp":1741609585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772368225000265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":43,"alternative-id":["S2772368225000265"],"URL":"https:\/\/doi.org\/10.1016\/j.lansea.2025.100555","relation":{},"ISSN":["2772-3682"],"issn-type":[{"value":"2772-3682","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges associated with dapsone for leprosy treatment in Indonesia - urgent need for access to alternative antimicrobial drugs","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Southeast Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lansea.2025.100555","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100555"}}